Market closedADR

Grifols/GRFS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Ticker

GRFS
Trading on

Industry

Biotechnology
Headquarters

Employees

23,505

Grifols Metrics

BasicAdvanced
$6.9B
Market cap
35.60
P/E ratio
$0.24
EPS
0.72
Beta
-
Dividend rate
$6.9B
0.72
$12.15
$5.30
1M
1.682
0.777
105.509
138.692
1.60%
2.47%
2.82%
35.598
0.842
1.13
-1.44
74.196
5.12%
-2,766.81%
9.42%
-38.79%

What the Analysts think about Grifols

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Grifols stock.

Grifols Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Grifols Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy GRFS

$

Sign up or log in to buy
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Grifols stock?

Grifols (GRFS) has a market cap of $6.9B as of October 10, 2024.

What is the P/E ratio for Grifols stock?

The price to earnings (P/E) ratio for Grifols (GRFS) stock is 35.6 as of October 10, 2024.

Does Grifols stock pay dividends?

No, Grifols (GRFS) stock does not pay dividends to its shareholders as of October 10, 2024.

When is the next Grifols dividend payment date?

Grifols (GRFS) stock does not pay dividends to its shareholders.

What is the beta indicator for Grifols?

Grifols (GRFS) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.